Physician profile
Mitchell R Lester
NPI 1881785673
$2,376.35
in general payments reported to CMS, 2019-2025
26 companies · $50.00 in 2025
The $50.00 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $256 · 2021: $528 · 2022: $908 · 2024: $52.17 · 2025: $50.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $102.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $322.16 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $257.27 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $184.55 | 2019-2022 | |
| Csl Behring | $182.37 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $149.60 | 2020-2022 | |
| Alk-Abello, INC | $141.27 | 2020-2022 | |
| Kaleo, INC. | $140.81 | 2019-2022 | |
| Pfizer INC. | $123.07 | 2019-2022 | |
| Glaxosmithkline, LLC. | $112.90 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.40 | 2020-2022 | |
| Blueprint Medicines Corporation | $102.17 | 2024-2025 | Ayvakit |
| Merck Sharp & Dohme LLC | $71.45 | 2019 | |
| Covis Pharma Gmbh | $63.15 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $59.44 | 2022 | |
| Grifols USA, LLC | $55.43 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $51.72 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $43.91 | 2021-2022 | |
| Genzyme Corporation | $41.15 | 2021-2022 | |
| Phadia US INC. | $36.26 | 2019 | |
| Amgen INC. | $33.42 | 2022 | |
| Pharming Healthcare, INC. | $21.16 | 2021 | |
| Genentech USA, INC. | $20.08 | 2020 | |
| Uswm, LLC | $19.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.65 | 2019 | |
| Optinose US, INC. | $12.73 | 2019 | |
| Seqirus USA INC | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Lester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.